RU2209247C2 - Рекомбинантная молекула днк, кодирующая белок альфа-антигена streptococcus группы в, плазмидный вектор - Google Patents

Рекомбинантная молекула днк, кодирующая белок альфа-антигена streptococcus группы в, плазмидный вектор Download PDF

Info

Publication number
RU2209247C2
RU2209247C2 RU95113472/13A RU95113472A RU2209247C2 RU 2209247 C2 RU2209247 C2 RU 2209247C2 RU 95113472/13 A RU95113472/13 A RU 95113472/13A RU 95113472 A RU95113472 A RU 95113472A RU 2209247 C2 RU2209247 C2 RU 2209247C2
Authority
RU
Russia
Prior art keywords
group
streptococcus
protein
proteins
sequence
Prior art date
Application number
RU95113472/13A
Other languages
English (en)
Russian (ru)
Other versions
RU95113472A (ru
Inventor
Джеймс Л. МИЧЕЛ (US)
Джеймс Л. МИЧЕЛ
Деннис Л. КАСПЕР (US)
Деннис Л. КАСПЕР
Фредерик М. ОСЬЮБЕЛ (US)
Фредерик М. ОСЬЮБЕЛ
Лоренс С. МЭДДОФФ (US)
Лоренс С. МЭДДОФФ
Original Assignee
Дзе Дженерал Хоспитал Корпорейшн
Брихэм энд Уимен'з Хоспитал
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Дженерал Хоспитал Корпорейшн, Брихэм энд Уимен'з Хоспитал filed Critical Дзе Дженерал Хоспитал Корпорейшн
Publication of RU95113472A publication Critical patent/RU95113472A/ru
Application granted granted Critical
Publication of RU2209247C2 publication Critical patent/RU2209247C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
RU95113472/13A 1992-11-02 1993-11-02 Рекомбинантная молекула днк, кодирующая белок альфа-антигена streptococcus группы в, плазмидный вектор RU2209247C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96886692A 1992-11-02 1992-11-02
US07/968,866 1992-11-02

Publications (2)

Publication Number Publication Date
RU95113472A RU95113472A (ru) 1999-05-10
RU2209247C2 true RU2209247C2 (ru) 2003-07-27

Family

ID=25514876

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95113472/13A RU2209247C2 (ru) 1992-11-02 1993-11-02 Рекомбинантная молекула днк, кодирующая белок альфа-антигена streptococcus группы в, плазмидный вектор

Country Status (14)

Country Link
EP (1) EP0669985A1 (xx)
JP (1) JPH08505282A (xx)
KR (1) KR100349331B1 (xx)
AU (1) AU689452B2 (xx)
CA (1) CA2146926A1 (xx)
FI (1) FI951979A (xx)
HU (1) HU220198B (xx)
IL (1) IL107458A0 (xx)
NO (1) NO951629L (xx)
NZ (1) NZ258684A (xx)
PL (1) PL177302B1 (xx)
RU (1) RU2209247C2 (xx)
WO (1) WO1994010317A2 (xx)
ZA (1) ZA938171B (xx)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2528858C2 (ru) * 2008-08-28 2014-09-20 Новартис Аг Дисплей на поверхности клеток полипептидных изоформ на основе прочитывания терминирующего кодона

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015889A (en) * 1993-03-19 2000-01-18 Gunnar Lindahl Protein rib, a cell surface protein that confers immunity to many strains of the group B streptococcus: process for purification of the protein, reagent kit and pharmaceutical composition
US6284884B1 (en) 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
US6426074B1 (en) * 1997-03-19 2002-07-30 The Brigham And Women's Hospital Inc. Group B Streptococcus vaccine
US7098182B2 (en) 1998-07-27 2006-08-29 Microbial Technics Limited Nucleic acids and proteins from group B streptococcus
CA2337102A1 (en) * 1998-07-27 2000-02-10 Richard William Falla Le Page Nucleic acids and proteins from group b streptococcus
US6890539B2 (en) 1998-12-22 2005-05-10 Microscience, Ltd. Genes and proteins, and their use
CN101486756A (zh) 1998-12-22 2009-07-22 微科学有限公司 外表面蛋白质及其基因和用途
GB9910375D0 (en) 1999-05-05 1999-06-30 Lindahl Gunnar Vaccine composition
WO2002031156A2 (en) * 2000-10-13 2002-04-18 Shire Biochem Inc. Bvh-a2 and bvh-a3 antigens of group b streptococcus
AU2004220590B2 (en) * 2003-03-07 2010-02-18 Inhibitex, Inc. Polysaccharide - Staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
RU2487890C2 (ru) * 2007-04-16 2013-07-20 МинерваКС Апс Слитый белок, способный индуцировать защитный иммунитет против стрептококка группы в, и вакцина, содержащая такой белок
RU2757426C2 (ru) 2015-10-21 2021-10-15 МинерваКС Апс Иммунногенный слитый белок
WO2017114655A1 (en) 2015-12-30 2017-07-06 Minervax Aps Immunogenic complex for eliciting protective immunity against group b streptococcus
CA3066020A1 (en) 2017-06-16 2018-12-20 Glaxosmithkline Biologicals Sa Method of treatment
CA3161857A1 (en) 2019-11-22 2021-05-27 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
EP4066854A1 (en) 2021-03-29 2022-10-05 MinervaX Immunogenic fusion protein

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0302887B1 (en) * 1986-04-16 1994-06-22 The Brigham And Women's Hospital, Inc. Bacterial antigens, antibodies, vaccines, and methods of manufacture
IL95578A (en) * 1989-09-15 1998-08-16 Gen Hospital Corp A vaccine made from polysaccharide and protein

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. MICHEl et al., J. Inf. Immun., v.59, №6, 1991, р.2023-2028. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2528858C2 (ru) * 2008-08-28 2014-09-20 Новартис Аг Дисплей на поверхности клеток полипептидных изоформ на основе прочитывания терминирующего кодона

Also Published As

Publication number Publication date
JPH08505282A (ja) 1996-06-11
HUT70981A (en) 1995-11-28
PL308555A1 (en) 1995-08-21
IL107458A0 (en) 1994-02-27
FI951979A (fi) 1995-06-29
CA2146926A1 (en) 1994-05-11
HU220198B (hu) 2001-11-28
ZA938171B (en) 1995-03-07
FI951979A0 (fi) 1995-04-26
NO951629L (no) 1995-07-03
KR950704492A (ko) 1995-11-20
NZ258684A (en) 1997-04-24
AU5665494A (en) 1994-05-24
AU689452B2 (en) 1998-04-02
NO951629D0 (no) 1995-04-28
EP0669985A1 (en) 1995-09-06
PL177302B1 (pl) 1999-10-29
KR100349331B1 (ko) 2003-01-06
WO1994010317A2 (en) 1994-05-11
WO1994010317A3 (en) 1994-07-07

Similar Documents

Publication Publication Date Title
US6342223B1 (en) Immunogenic composition for group B Streptococcus
RU2209247C2 (ru) Рекомбинантная молекула днк, кодирующая белок альфа-антигена streptococcus группы в, плазмидный вектор
EP0571538B1 (en) Structural gene of pneumococcal protein
US6426074B1 (en) Group B Streptococcus vaccine
EP0695803A2 (en) Epitopic regions of pneumococcal surface protein A
RU2113234C1 (ru) Вакцина, способная сообщать хозяину иммунитет против инфекции, вызванной streptococcus группы b, способ предупреждения инфекции, вызванной streptococcus группы b, и способ ослабления инфекции, вызванной streptococcus группы b
WO1998024927A1 (en) Compositions and methods for administering pneumococcal dna
AU722078B2 (en) Conjugate vaccine against group B Streptococcus
PT100193A (pt) Gene estrutural de proteina pneumococica

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20041103